Tandem Mobi Pump and the Dexcom G7 CGM Are Now Connected

On May 29, 2024, Tandem Diabetes Care and Dexcom, Inc. announced that the Dexcom G7 continuous glucose monitor (CGM) and the Tandem Mobi insulin pump are now completely compatible.

Tandem Mobi connects with Dexcom G7 CGM—as well as the Dexcom G6 CGM—to predict blood-sugar levels 30 minutes in advance. It also automatically adjusts insulin, if needed, to help prevent highs and lows.

With the Tandem Mobi/Dexcom G7 integration, Tandem Mobi users can also experience:

• More time in closed loop with the Dexcom G7’s 30-minute sensor warm-up time.
• Additional discretion with Dexcom G7’s low-profile, all-in-one wearable.

Control-IQ, an innovative hybrid closed-loop automated insulin delivery tool that predicts and helps avoid high and low blood sugar, is another feature of the Tandem Mobi. Control-IQ leads to improved time in range throughout the day and night.

In July 2023, the Tandem Mobi received FDA clearance for people with diabetes ages six and up. In early 2024, Tandem Mobi launched in the United States. It is the world’s smallest and most durable automated insulin delivery (AID) system.

“With this integration, we’re providing more flexibility for our customers and continuing our decade-long partnership with Dexcom to bring innovative and discrete solutions to people living with diabetes,”  said John Sheridan, president and chief executive officer of Tandem Diabetes Care.

News coverage by the Beyond Type 1 team is operated independently from any content partnerships.

Beyond Type 1 maintains full editorial control of all content published on our platforms.